Spiegelmer Aptamers Offer Innovative Theranostic Potential for Breast Cancer Management

Globally, breast cancer remains a leading cause of cancer-related mortality, necessitating urgent advancements in diagnostic and therapeutic strategies. Current approaches often face challenges due to tumor heterogeneity and limitations in specificity or systemic toxicity. While traditional aptamers offer high affinity and tumor penetration, their clinical utility is hampered by instability in biological systems. Spiegelmers, a novel class of L-nucleotide-based aptamers, address this critical gap by providing intrinsic nuclease resistance and prolonged serum half-life, making them highly attractive for next-generation theranostic applications.

This comprehensive review synthesizes existing research on Spiegelmer aptamers, detailing their unique biophysical properties, mechanisms of action, and diverse applications within breast cancer diagnostics and therapeutics. It evaluates their potential for advanced molecular imaging, including MRI and PET, when conjugated to various labels. Furthermore, the review explores their utility in targeted drug delivery, as well as their roles in photodynamic and photothermal therapies. It also examines their capacity to inhibit oncogenic microRNAs, such as miR-155, highlighting new avenues for treating aggressive subtypes like triple-negative breast cancer.

Spiegelmers demonstrate superior biostability and high binding specificity to a diverse range of targets, including proteins, peptides, and microRNAs, primarily due to their unique L-nucleotide composition which confers intrinsic nuclease resistance and a prolonged serum half-life. This enhanced stability significantly improves upon the limitations of conventional D-aptamers. For diagnostic applications, spiegelmers show strong potential for molecular imaging via MRI and PET when conjugated to fluorescent or radioactive labels, enabling precise tumor visualization. They are also highly effective for targeted drug delivery, ensuring therapeutic agents are concentrated at the tumor site while minimizing off-target effects. > Crucially, spiegelmers can specifically inhibit oncogenic microRNAs, such as miR-155, offering novel therapeutic strategies for challenging breast cancer subtypes like triple-negative breast cancer.